Is Tirzepatide Safe? Side Effects, Warnings and What Monitoring Looks Like

The finding that shapes the label is a two-year carcinogenicity study in rats, in which tirzepatide produced a dose- and duration-dependent increase in thyroid C-cell adenomas and carcinomas at plasma exposures in the clinical range. The same label records that a six-month study in a transgenic mouse strain found no tumors and that tirzepatide was not genotoxic. Rodent C-cells carry far more GLP-1 receptors than human C-cells, which is why the finding is treated as a warning of unknown human relevance rather than a demonstrated human harm. The label says exactly that: whether tirzepatide causes thyroid C-cell tumors in humans is unknown.

Peak concentration comes about 24 hours after a subcutaneous dose, bioavailability is roughly 80 percent, albumin binding 99 percent, and the elimination half-life about five to six days, which is why it is dosed weekly and takes about four weeks to reach steady state. A phase 1 clamp study in adults with type 2 diabetes (The Lancet Diabetes & Endocrinology, 2022) described improved insulin secretion and sensitivity over 28 weeks against placebo and semaglutide.

The first approval, as Mounjaro in May 2022, rested on SURPASS. SURPASS-1 (The Lancet, 2021) was 40 weeks against placebo; SURPASS-2 (New England Journal of Medicine, 2021) compared tirzepatide with semaglutide 1 mg in 1,879 adults for 40 weeks; SURPASS-3 (The Lancet, 2021) with insulin degludec over 52 weeks; SURPASS-4 (The Lancet, 2021) with insulin glargine in adults at elevated cardiovascular risk for up to 104 weeks, with no excess of major cardiovascular events; SURPASS-5 (JAMA, 2022) added it to titrated glargine. The Mounjaro label pools seven trials: 5,119 adults treated for a mean of 48 weeks.

The weight-management approval, as Zepbound in November 2023, rested on SURMOUNT. SURMOUNT-1 (New England Journal of Medicine, 2022) randomized 2,539 adults with obesity or overweight and without diabetes to 5, 10 or 15 mg or placebo for 72 weeks; SURMOUNT-2 (The Lancet, 2023) did the same in adults with type 2 diabetes. SURMOUNT-3 (Nature Medicine, 2023) started the drug after a 12-week lifestyle program; SURMOUNT-4 (JAMA, 2024) treated everyone for 36 weeks and then randomized them to continue or switch to placebo, which describes what happens to weight on withdrawal. SURMOUNT-OSA (New England Journal of Medicine, 2024) covered sleep apnea with obesity, and SURMOUNT-5 (New England Journal of Medicine, 2025) compared tirzepatide directly with semaglutide 2.4 mg over 72 weeks. Across all of them, gastrointestinal events were the most common adverse effects, mostly mild to moderate and concentrated in dose escalation.

The largest single safety dataset is SURPASS-CVOT (New England Journal of Medicine, 2025), which compared tirzepatide with dulaglutide, an approved GLP-1 receptor agonist, in adults with type 2 diabetes and established cardiovascular disease and met its noninferiority endpoint: a large high-risk population, an active comparator, and no new category of harm identified.

All of the above describes Mounjaro and Zepbound. Compounded tirzepatide contains the same molecule, so its pharmacology and contraindications are the same; what does not transfer is the manufacturer's finished-product data: the approved formulation, the stability program and the FDA review of that specific product. Pepti's tirzepatide is compounded to a prescription by a state-licensed, FDA-registered US pharmacy and is not an FDA-approved product; the pharmacy's testing is on the quality page and in the lab results.

The label's pool of SURMOUNT-1 and 2 covers 2,519 adults treated for up to 72 weeks. Nausea: 25, 29 and 28 percent on 5, 10 and 15 mg against 8 percent on placebo. Diarrhea: 19, 21 and 23 against 8. Vomiting: 8, 11 and 13 against 2. Constipation: 17, 14 and 11 against 5. Abdominal pain and dyspepsia each 9 to 10 percent against 4 to 5; injection-site reactions 6 to 8 against 2; fatigue 5 to 7 against 3; hypersensitivity, mostly rash and itching, 5 against 3; burping, hair loss and reflux each 4 to 5 against 1 or 2; dizziness 4 to 5 against 2; low blood pressure 1.6 against 0.1, higher in people already on antihypertensives. Some gastrointestinal event was reported by 56 percent on any dose and 30 percent on placebo. Two things stand out: placebo rates are not zero, so the excess attributable to the drug is smaller than the raw figure, and the rates barely change between 5 mg and 15 mg, which suggests how fast the dose is raised matters more than where it ends up.

The type 2 diabetes population reported less: nausea 12, 15 and 18 percent at 5, 10 and 15 mg against 4 percent; diarrhea 12, 13 and 17 against 9; decreased appetite 5, 10 and 11 against 1; vomiting 5, 5 and 9 against 2; any gastrointestinal event 37 to 44 percent against 20. Rates are population-specific, which is one reason your own experience will not match a table exactly.

Across SURMOUNT-1 and 2, 4.8, 6.3 and 6.7 percent of people on 5, 10 and 15 mg stopped permanently because of an adverse reaction, against 3.4 percent on placebo, most in the first months for gastrointestinal reasons (1.9, 3.3 and 4.3 percent against 0.5). Roughly one person in twenty stops for side effects; most people who have them continue.

Most nausea, vomiting and diarrhea occurred during dose escalation and decreased over time. That is why the approved schedule starts everyone at 2.5 mg weekly for four weeks, a dose for initiation rather than maintenance, increases in 2.5 mg steps no sooner than every four weeks, and directs prescribers to consider a lower maintenance dose when a higher one is not tolerated; 5, 10 and 15 mg are all approved maintenance doses. Pepti's tirzepatide comes in dose-specific vials at the same rungs with the directions printed on each, and the physician decides when, and whether, to move up.

Both approved labels open with a boxed warning: in rats, tirzepatide causes dose- and duration-dependent thyroid C-cell tumors at clinically relevant exposures, and whether it does so in humans is unknown. The consequence is a hard contraindication for anyone with a personal or family history of medullary thyroid carcinoma or with multiple endocrine neoplasia syndrome type 2, and an instruction to tell patients the symptoms that warrant attention: a mass in the neck, difficulty swallowing, shortness of breath, persistent hoarseness. What the label does not recommend is also informative: routine calcitonin tests and thyroid ultrasound are described as of uncertain value and likely to generate unnecessary procedures, because calcitonin is non-specific and thyroid nodules are common. That is why a Pepti physician asks carefully about family history rather than ordering a scan.

Pancreatitis has been observed with GLP-1 receptor agonists and with tirzepatide, and the instruction is unambiguous: if suspected, discontinue. The rates are lower than most people assume. In the pooled weight-reduction trials, adjudicated acute pancreatitis occurred in 0.2 percent on tirzepatide and 0.2 percent on placebo (0.14 versus 0.15 per 100 patient-years); in the diabetes trials 0.23 versus 0.11 per 100 patient-years; in the smaller sleep apnea trials 0.84 against none. The signal is real but small, and the response is recognition: persistent or severe abdominal pain, sometimes radiating to the back, that does not behave like dose-increase nausea.

Rapid weight reduction by any means raises gallstone risk, and the label attributes the trial events to it. Gallstones were reported in 1.1 percent on tirzepatide against 1 percent on placebo, gallbladder inflammation in 0.7 against 0.2, and gallbladder removal in 0.2 against none. Right upper abdominal pain, especially with fever or yellowing skin, is what to report.

Tirzepatide is not toxic to the kidney; no dose adjustment is needed in renal impairment. The risk is indirect: post-marketing reports of acute kidney injury, some needing dialysis, mostly in people whose vomiting or diarrhea led to dehydration. Prescribers are told to monitor kidney function in anyone reporting side effects that could cause fluid loss, particularly during initiation and escalation.

Beyond common nausea, the label carries a separate warning for severe gastrointestinal reactions, reported in 1.7, 2.5 and 3.1 percent at 5, 10 and 15 mg against 1 percent on placebo, and after marketing across the GLP-1 class. Tirzepatide is not recommended in severe gastroparesis, because it slows an already slow stomach further.

Mild hypersensitivity, mostly rash and itching, ran at about 5 percent against 3. Serious reactions are different: anaphylaxis and angioedema have been reported after marketing, and severe hypersensitivity occurred in 0.1 percent of trial participants against none on placebo. A previous serious reaction to tirzepatide or any excipient is a contraindication, and the label advises caution after angioedema or anaphylaxis with any other GLP-1 receptor agonist. Facial or throat swelling, widespread rash or breathing difficulty is an emergency first and a message to your physician second.

Tirzepatide stimulates insulin release only when glucose is high, so alone it rarely drives blood sugar dangerously low. The risk is in combination: in SURMOUNT-2, people with type 2 diabetes had a 4.2 percent rate of glucose below 54 mg/dL against 1.3 on placebo, and 10.3 percent among those also taking a sulfonylurea against 2.1 for those not. Prescribers are directed to consider reducing insulin or a secretagogue when tirzepatide starts and to teach every patient the signs, since hypoglycemia has also been reported in adults without diabetes.

People with existing diabetic retinopathy can see temporary worsening when glucose improves quickly, and the label asks that they be monitored. And because gastric emptying is delayed, there have been rare post-marketing reports of pulmonary aspiration under general anesthesia or deep sedation with food still in the stomach; patients are instructed to tell every provider before any planned procedure. Whether to hold a dose beforehand is the anesthesiologist's decision with your prescriber.

The caution most often missed. Because emptying slows most after the first dose and after each increase, an oral contraceptive taken in those windows may be absorbed less: a single 5 mg dose reduced the peak concentration of ethinyl estradiol, norgestimate and norelgestromin by 59, 66 and 55 percent and total exposure by 20 to 23 percent. The label's advice is to switch to a non-oral contraceptive, or add a barrier method, for four weeks after starting and four weeks after each dose escalation. This matters doubly because weight reduction can restore ovulation; do peptides affect fertility covers that.

The same mechanism applies to any oral drug, and the label singles out medicines with a narrow therapeutic window, warfarin being the example, for monitoring at the start. Acetaminophen shows the shape of it: peak concentration fell 55 percent after a first 5 mg dose, but by week 6 on 15 mg there was no meaningful effect. The label also lists a limitation of use: tirzepatide alongside any other tirzepatide product or any GLP-1 receptor agonist is not recommended. Tirzepatide and semaglutide are alternatives, never a pair.

Tirzepatide is not used in pregnancy. The label states that weight loss offers no benefit to a pregnant patient and may cause fetal harm, that human data are insufficient, and that in animal studies fetal growth reductions and abnormalities occurred at clinically relevant exposures; the instruction is to stop when pregnancy is recognized. On breastfeeding: in a lactation study of 11 women given a single 5 mg dose, tirzepatide was undetectable in 164 of 171 milk samples and the remainder totaled under 0.02 percent of the maternal dose; effects on a breastfed infant are unstudied. Pepti physicians do not prescribe it in either situation.

A Zepbound single-dose vial contains tirzepatide, sodium chloride, sodium phosphate and water; the multi-dose presentations add benzyl alcohol, glycerin and phenol as preservatives. Pepti's compounded tirzepatide is a multi-dose vial that includes cyanocobalamin, shown on the product page's composition line. Its beyond-use date runs from first puncture and is printed on the label; one vial per fill, used within that window, is the rule.

Tirzepatide is FDA approved as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management and for obstructive sleep apnea in adults with obesity, both made by Eli Lilly. Compounded tirzepatide is neither product and is not FDA approved; no compounded medication is.

From late 2022 tirzepatide was on the FDA's shortage list, which allows compounding of a drug that is otherwise a copy of an approved product. The FDA declared the shortage resolved on 2 October 2024, reconsidered after the Outsourcing Facilities Association sued, and reaffirmed the decision on 19 December 2024, giving 503A pharmacies until 18 February 2025 and 503B facilities until 19 March 2025 to wind down. The FDA's shortage database lists tirzepatide injection as resolved today.

With no shortage, the ordinary 503A rules govern. The FDA's guidance page for compounders, last updated 1 April 2026, defines a compounded drug as "essentially a copy" when it has the same active ingredient in the same, similar or easily substitutable strength by the same route, and confirms that a state-licensed 503A pharmacy may still compound one for an identified patient when the prescriber documents that it produces a significant difference for that patient. That is the pathway a Pepti prescription travels.

On 30 April 2026 the FDA proposed to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list, having not identified a clinical need for outsourcing facilities to compound them from bulk substances. The comment period was extended to 30 July 2026 and no final determination had been published at the time of writing. It concerns 503B bulk compounding and does not change the 503A framework above.

The FDA's page on its concerns with unapproved GLP-1 drugs, updated 1 September 2026, makes four points: compounded drugs are not reviewed by the agency for safety, effectiveness or quality; they should be used only when a patient's needs cannot be met by an approved drug; the agency has received adverse event reports for compounded semaglutide and tirzepatide, with dosing error the recurring theme, from patients drawing the wrong volume from a multi-dose vial and from schedules that exceed the label; and counterfeits sold outside the pharmacy system may contain the wrong ingredient or none. Those concerns are why a Pepti prescription is built the way it is: dose-specific vials at the label's own rungs so the volume drawn is the same at every strength, directions printed on the vial in milliliters and syringe units, escalation no faster than the approved schedule and only when the physician decides, and a named licensed pharmacy behind every vial with its testing published.